MediPharm Labs Corp. specializes in producing and selling pharmaceutical-quality cannabis oil and concentrates. The company demonstrates strengths with a solid gross margin of 43.2% and a healthy current ratio of 2.69, indicating good liquidity. However, concerns arise from its low EBITDA and net margins, both at 0.0%, suggesting profitability challenges. The low market cap of $27.77M relative to its margins may indicate undervaluation, but the lack of return on equity and assets raises questions about overall financial performance.
Loading financial metrics...
Company posted a loss of $-5.0M over the last year, representing 12.0% of revenue.
Revenue decreased 6.7% year-over-year from $44.5M to $41.5M.
Operating margin expanded by 7.5pp, demonstrating strong operational leverage.
Both gross margin (+2.4pp) and operating margin (+7.5pp) are expanding simultaneously, indicating the company is scaling profitably.
Fortress balance sheet: cash covers total debt 23×, providing significant financial flexibility.
Excellent liquidity with current ratio of 2.7x ensures operational stability.
Low debt-to-revenue ratio of 1.0% indicates conservative financial management.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Drug Manufacturers - Specialty & Generic companies of a similar size
Based on 2026-Q2 (June 30, 2026)